While GLP-1 medications can help individuals achieve significant weight loss and improve blood sugar regulation in the short term, the long-term sustainability of these benefits largely depends on continued lifestyle changes and medications
This genetic insight is especially valuable if your first pre-pregnancy course produced variable results
Decision framework: Start existing treatments (semaglutide or tirzepatide) if: Your health risks from obesity are significant and immediate (uncontrolled diabetes, severe sleep apnea, cardiovascular disease) You have access to approved therapies through insurance or can afford them You need proven, FDA-approved medications with established safety profiles Waiting 1-2+ years for retatrutide approval doesnt align with your health timeline Consider waiting if: Youre currently at a stable weight with controlled health conditions Youve tried semaglutide or tirzepatide and hit a plateau but tolerated them well Youre in a position to potentially enroll in a retatrutide clinical trial You understand waiting means continued health risks from obesity Dont wait if: You think retatrutide will be a magic bullet with no downsides Your doctor is recommending treatment now for medical reasons Youre using waiting for the next best thing as an excuse to avoid addressing the problem The lifestyle component is non-negotiable regardless of which medication you use: High protein intake (0.7-1g per pound of body weight daily) to preserve muscle during weight loss
Every claim cites a primary source, updated as new data lands
This work was supported by the BMBF/ZonMW program Innosystox (SysBioToP), and the DZ-foundation
Secondly, do these unimolecular agents target both receptors in the same cell, different cells in different tissues, or both
